MX2024002720A - Nanocuerpos anti-4-1bb. - Google Patents

Nanocuerpos anti-4-1bb.

Info

Publication number
MX2024002720A
MX2024002720A MX2024002720A MX2024002720A MX2024002720A MX 2024002720 A MX2024002720 A MX 2024002720A MX 2024002720 A MX2024002720 A MX 2024002720A MX 2024002720 A MX2024002720 A MX 2024002720A MX 2024002720 A MX2024002720 A MX 2024002720A
Authority
MX
Mexico
Prior art keywords
nanobodies
antibodies
bispecific
cancer
treat
Prior art date
Application number
MX2024002720A
Other languages
English (en)
Spanish (es)
Inventor
Wentao Huang
Runsheng Li
Original Assignee
Lanova Medicines Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lanova Medicines Ltd filed Critical Lanova Medicines Ltd
Publication of MX2024002720A publication Critical patent/MX2024002720A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2024002720A 2021-08-31 2022-08-29 Nanocuerpos anti-4-1bb. MX2024002720A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021115621 2021-08-31
PCT/CN2022/115536 WO2023030258A1 (en) 2021-08-31 2022-08-29 Anti-4-1bb nanobodies

Publications (1)

Publication Number Publication Date
MX2024002720A true MX2024002720A (es) 2024-04-12

Family

ID=85410851

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024002720A MX2024002720A (es) 2021-08-31 2022-08-29 Nanocuerpos anti-4-1bb.

Country Status (10)

Country Link
US (2) US20240383993A1 (cg-RX-API-DMAC7.html)
EP (1) EP4396234A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024530325A (cg-RX-API-DMAC7.html)
KR (1) KR20240049829A (cg-RX-API-DMAC7.html)
CN (1) CN118176211A (cg-RX-API-DMAC7.html)
AU (1) AU2022336889A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230481A1 (cg-RX-API-DMAC7.html)
IL (1) IL311144A (cg-RX-API-DMAC7.html)
MX (1) MX2024002720A (cg-RX-API-DMAC7.html)
WO (1) WO2023030258A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024530325A (ja) 2021-08-31 2024-08-16 ラノバ メディシンズ リミテッド 抗4-1bbナノボディ
AU2024229974A1 (en) * 2023-02-28 2025-09-11 LaNova Medicines Limited Ceacam5-dependent 4-1bb-agonistic bispecific antibodies
WO2025214249A1 (en) * 2024-04-12 2025-10-16 Suzhou Biomissile Pharmaceuticals Co., Ltd. Anti-4-bb single domain antibodies, bispecific antibodies and uses thereof
WO2026075820A1 (en) * 2024-10-03 2026-04-09 Modernatx, Inc. 4-1bb binding molecules, nucleic acids encoding same, and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
CN104829730A (zh) 2015-04-14 2015-08-12 苏静 一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用
IL304871A (en) * 2016-01-11 2023-10-01 Inhibrx Inc Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses
US10174122B2 (en) * 2017-01-06 2019-01-08 Eutilex Co., Ltd. Anti-human 4-1BB antibodies and uses thereof
CA3082297A1 (en) * 2017-11-13 2019-05-16 Crescendo Biologics Limited Molecules that bind to cd137 and psma
JP7357616B2 (ja) * 2017-12-05 2023-10-06 中外製薬株式会社 Cd3およびcd137に結合する改変された抗体可変領域を含む抗原結合分子
TW201932491A (zh) * 2018-01-22 2019-08-16 大陸商江蘇恆瑞醫藥股份有限公司 抗4-1bb抗體、其抗原結合片段及其醫藥用途
CN108659131B (zh) 2018-05-28 2021-09-14 长春力太生物技术有限公司 一种抗ceacam-5的单域抗体及其应用
TW202035447A (zh) * 2018-07-04 2020-10-01 瑞士商赫孚孟拉羅股份公司 新穎雙特異性促效性4-1bb抗原結合分子
CN112646031B (zh) * 2019-10-10 2021-12-07 天境生物科技(上海)有限公司 抗4-1bb纳米抗体及其用途
CN117355540A (zh) 2021-05-21 2024-01-05 百济神州有限公司 抗cd137抗体和使用方法
JP2024530325A (ja) 2021-08-31 2024-08-16 ラノバ メディシンズ リミテッド 抗4-1bbナノボディ

Also Published As

Publication number Publication date
US20250320307A1 (en) 2025-10-16
KR20240049829A (ko) 2024-04-17
AU2022336889A1 (en) 2024-03-14
US12692318B2 (en) 2026-07-28
JP2024530325A (ja) 2024-08-16
US20240383993A1 (en) 2024-11-21
EP4396234A4 (en) 2025-07-16
CA3230481A1 (en) 2023-03-09
CN118176211A (zh) 2024-06-11
IL311144A (en) 2024-04-01
WO2023030258A1 (en) 2023-03-09
EP4396234A1 (en) 2024-07-10

Similar Documents

Publication Publication Date Title
CL2020003028A1 (es) Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos.
CL2020003179A1 (es) (divisional de solicitud 713-2015) anticuerpos anti-cd3, moleculas de union a antígeno biespecificas que se unen a cd3 y cd20; y usos de los mismos.
CL2022001671A1 (es) Inhibidores de sos1
CL2023002048A1 (es) Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos
MX2021011209A (es) Novedosos inhibidores de molécula pequeña de factores de transcripción tead.
CO2021012719A2 (es) Métodos para producción de células car-nk y uso de las mismas
CO2021016907A2 (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
CR20240181A (es) Moléculas de unión a cd19 y usos de las mismas
CL2018003758A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458)
BR112021023026A2 (pt) Moléculas de ligação biespecíficas anti-ror1/anti-cd3
MX2021011608A (es) Metodos ex vivo para producir celulas t terapeuticas y composiciones y metodos afines.
BR112018067679A2 (pt) células que expressam múltiplas moléculas do receptor de antígeno quimérico (car) e seu uso
MX2018013072A (es) Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
CO6630166A2 (es) Síntesis esteroselectiva de activos que contienen fósforo
CO2022008272A2 (es) Agentes de unión a ilt3 y métodos de uso de los mismos
MX381760B (es) Tintas cerca de infrarrojo (nir) dirigidas por antìgeno prostàtico especìfico de membrana (psma) y sus usos.
MX2016012094A (es) Composiciones de anticuerpos para tratamiento tumoral.
MX2019013117A (es) Moleculas de union al dominio de fibronectina de tipo iii del receptor del factor de crecimiento epidermico y del receptor del factor de crecimiento de hepatocitos (egfr y c-met).
MX2021003654A (es) Metodo para seleccionar neoepitopes.
MX2020011914A (es) Anticuerpos anti-dll3 y usos de los mismos.
EA201792581A1 (ru) Способы применения биспецифических cd33- и cd3- связывающих белков
MX2022016544A (es) Agentes de union a lair-1 y metodos para su uso.
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
MX2016009444A (es) Anticuerpos humanos a ligando de muerte programada 1 (pd-l1).
MX2025009913A (es) Anticuerpos anti-cd3 y metodos para su uso